Biomarkers for Lung Cancer Screening and Detection
Abstract
Lung cancer is the leading worldwide cause of cancer mortality, as it is often detected at an advanced stage. Since 2011, low-dose CT scan–based screening has promised a 20% reduction in lung cancer mortality. However, effectiveness of screening has been limited by eligibility only for a high-risk population of heavy smokers and a large number of false positives generated by CT. Biomarkers have tremendous potential to improve early detection of lung cancer by refining lung cancer risk, stratifying positive CT scans, and categorizing intermediate-risk pulmonary nodules. Three biomarker tests (Early CDT-Lung, Nodify XL2, Percepta) have undergone extensive validation and are available to the clinician. The authors discuss these tests, with their clinical applicability and limitations, current ongoing evaluation, and future directions for biomarkers in lung cancer screening and detection.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2020
- Source ID
- 10.1158/1055-9965.epi-20-0865
Entities
People
- Avrum Spira
- David Sidransky
- Edwin Justin Ostrin
- Samir M Hanash
Organizations
- American Lung Association-Southeast Region
- Boston University
- Johns Hopkins Hospital
- Johnson & Johnson
- National Cancer Institute
- National Institutes of Health
- University of Texas at Austin